CEO Grace Colón (InCarda)
Looking to repurpose an old drug to treat irregular heartbeats, InCarda raises $30M in first Series C close
A little less than two years after completing its $42 million Series B round, InCarda has returned to the venture well.
The San Francisco …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
